Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Newsoara Biopharma Co., Ltd. clinical trials
The registry lists 11 studies whose lead sponsor is Newsoara Biopharma Co., Ltd.. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 3, 2026.
Keep track of what changes. Save the Newsoara Biopharma Co., Ltd. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Newsoara Biopharma Co., Ltd..
- Newsoara Biopharma Co., Ltd.11 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 11 of 11.
- Evaluation of the Safety, Tolerability and Pharmacokinetics of HY6725 in Healthy Adult ParticipantsRecruitingNCT07262281Phase 1
- Evaluation of the Safety, Tolerability and Pharmacokinetics of HY8931 in Healthy Adult ParticipantsRecruitingNCT07281703Phase 1
- HPP737 Substance Balance Study in HumanNot yet recruitingNCT06584058Not applicable
- HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLCNot yet recruitingNCT06218940Phase 1
- HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis.CompletedNCT07712705Phase 3
- HPP737 in Adult Patients With Plaque PsoriasisCompletedNCT07712731Phase 3
- Safety and Efficacy of HPP737 in Adult Patients With Plaque PsoriasisCompletedNCT07707141Phase 2
- Safety, Tolerance and Pharmacokinetics of THR-1442 in Chinese Healthy SubjectsStatus unknownNCT05369078Phase 1
- Safety and Efficacy of THR-1442 Compared to Dapagliflozin as Add-on Therapy to Metformin in T2DMStatus unknownNCT05159882Phase 3
- Study to Evaluate LB1148 for Return of Gastrointestinal Function, Decrease Post-Operative IleusCompletedNCT05056935Phase 2
- Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy VolunteersStatus unknownNCT04714294Phase 1